Semaglutide 7mg tablets: which product are you actually looking at?

Why the 7mg semaglutide tablet question leads somewhere unexpected

When people search for semaglutide tablets 7mg, they are almost always looking for a tablet form of the weight-loss treatment they have read about online. That is completely understandable, semaglutide is a well-documented medicine, and the idea of a daily tablet rather than a weekly injection appeals to a lot of people.

The 7mg tablet, though, belongs to Rybelsus. Rybelsus comes in three strengths (3mg, 7mg and 14mg) and every one of them is licensed by the MHRA solely for controlling blood sugar in adults with type 2 diabetes. It is not authorised for weight management, and a prescriber working within UK licensing law cannot use it for that purpose. You can read more about where this dose sits in the broader picture on the Rybelsus 7mg page.

This distinction is not a technicality. The dosing schedules, the clinical evidence, the approved populations and the monitoring requirements differ between the two products. Treating them as interchangeable is a clinical risk, which is why the question of which product you actually need is the one a prescriber should answer first.

If you are interested in how oral semaglutide works more broadly, that context is worth having before you go further.

What the licensed weight-loss tablet actually looks like

The Wegovy tablet received MHRA approval on 11 June 2026, which made it the first oral GLP-1 weight-loss medicine licensed anywhere in Europe. NHS guidance on semaglutide draws a clear line between the diabetes and weight-management formulations.

The dosing schedule for the Wegovy tablet runs 1.5mg, then 4mg, then 9mg, reaching a maintenance dose of 25mg, spending at least a month at each level before moving up. That is quite different from Rybelsus's 3mg, 7mg and 14mg steps. The two products share the same active ingredient but they are not the same medicine for regulatory or clinical purposes. More detail on how the weight-loss tablet is taken (including the morning routine and the 30-minute wait before food) is covered on the semaglutide tablets overview.

Phase 3 trial data (OASIS 4, 64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition) reported an average weight reduction of around 13.6% with the Wegovy tablet versus roughly 2.4% with placebo. Among participants who stayed fully adherent throughout, the average reached about 16.6%. Those figures come from the MHRA's approval announcement and Novo Nordisk's published data; they are trial results, not a guarantee of what any individual will experience.

One practical difference worth knowing: unlike the weekly injection pen, the Wegovy tablet does not need refrigeration. Room-temperature storage makes it considerably more travel-friendly. For a closer look at whether the weight-loss tablet route suits your situation, the semaglutide tablets for weight loss page covers the licensed product in more depth.

The factors that shape which semaglutide product a prescriber would consider

If you have type 2 diabetes and your GP has mentioned Rybelsus, the 7mg tablet may well be exactly what you are looking for, and your GP or diabetologist is the right person to discuss it with.

If weight management is your goal and you do not have a diabetes diagnosis, the relevant question is whether the Wegovy tablet (or the Wegovy weekly injection) could be appropriate. For the oral tablet, the licensed eligibility is adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not decide the outcome, a prescriber looks at the whole picture, including other medicines you take and your medical history.

Timing matters too. The Wegovy tablet has a specific morning routine: taken on an empty stomach with a small amount of plain water, then a wait of at least 30 minutes before food, drink or other oral medicines. Getting that consistently right affects how much semaglutide the body absorbs. The best time to take semaglutide tablets page goes into this in practical detail. Cost context is another factor many people weigh up; the where to buy semaglutide tablets in the UK page covers the access landscape honestly.

At nume, a real clinician reads every consultation, a GPhC-registered Independent Prescriber, not an automated system. They look at your medical history, your current medicines and your goals before deciding whether treatment is suitable. The Wegovy tablet is not yet available on the NHS, so private prescription is the current route for most people. If you would like to find out whether you are eligible, speaking to our prescribers is the straightforward next step.